Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000266805 | SCV000336091 | benign | not specified | 2015-10-13 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000399813 | SCV000366986 | likely benign | Deficiency of acetyl-CoA acetyltransferase | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000266805 | SCV000918384 | benign | not specified | 2018-02-05 | criteria provided, single submitter | clinical testing | Variant summary: ACAT1 c.*6dupC is located in the untranslated mRNA region downstream of the termination codon. MutationTaster predicts no impact on Poly(A) signal and the variant to be a polymorphism. The variant allele was found at a frequency of 0.0077 in 2132/276872 control chromosomes in the gnomAD database, including 50 homozygotes. The observed variant frequency is approximately 2.67 fold of the estimated maximal expected allele frequency for a pathogenic variant in ACAT1 causing Alpha-methylacetoacetic aciduria phenotype (0.0029), strongly suggesting that the variant is benign. To our knowledge, no occurrence of c.*6dupC in individuals affected with Alpha-methylacetoacetic aciduria and no experimental evidence demonstrating its impact on protein function have been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as benign. |
Gene |
RCV001711854 | SCV001944216 | benign | not provided | 2015-03-03 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000399813 | SCV001461800 | benign | Deficiency of acetyl-CoA acetyltransferase | 2020-09-16 | no assertion criteria provided | clinical testing |